Navigation Links
Therapies to improve biochemical functions hold promise as treatments for autism
Date:6/2/2011

Two promising new treatments to aid people with autism have shown effectiveness in pilot studies conducted by an Arizona State University professor and private researchers.

Several studies indicate that children with autism often have abnormalities in critical biochemical functions that help maintain health specifically methylation, glutathione, and mitochondrial functions.

Methylation turns proteins in the body on and off including DNA and RNA a function that controls gene activity.

Glutathione, a primary antioxidant, provides a defense against toxic metals in the body. Mitochondria are essentially the "factories" inside body cells that produce energy.

The research team has been developing therapies aimed at restoring or improving these functions in people with autism experiencing abnormalities.

The complete study is published in the medical journal Autism Insights, and is available online at http://la-press.com/article.php?article_id=2665

The team includes:

  • James Adams, a professor in the School for Engineering of Matter, Transport and Energy, one of ASU's Ira A. Fulton Schools of Engineering
  • Stuart Freedenfeld, physician and medical director with Stockton Family Practice, in Stockton, N.J.
  • Tapan Audhya, a biochemist with the Health Diagnostics and Research Institute, in South Amboy, N.J.
  • Kim Hamada, a registered nurse with Stockton Family Practice.

A common feature of the abnormalities the researchers are studying is that they are affected directly or indirectly by levels of specific substances produced by the body ribose and nicotinamide adenine dinucleotide, or NADH.

Use of ribose and NADH supplements have been reported to boost levels of adenosine-5'-triphosphate, or ATP a primary fuel source for the body and the brain. The supplements have also been shown to be helpful in treating chronic fatigue.

The research team explored use of ribose and NADH supplements as treatments for autism in two parallel studies using ribose and NADH.

One study investigated the effect of supplementation with NADH, an important co-factor for many enzymatic reactions in the body.

Another study investigated the effect of supplementation with ribose, a special sugar made by the body from glucose.

The studies found use of ribose and NADH supplements had similar effects, boosting levels of methylation, glutathione and ATP after only two weeks of therapy.

Levels of ribose and NADH also improved substantially, without adverse effects. After just two weeks of therapy, one child in each group was reported to have some improvement in energy level.

The biochemistry of both NADH and ribose is well-established, as well as how both affect production of ATP, glutathione and methylation. Details are provided in the article in Autism Insights.

Adams points out that both treatments use products that are available as over-the-counter nutritional supplements.

Larger and more formal studies are needed to confirm the benefits of ribose and NADH supplements, Freedenfeld says.

But "these therapies appear to be safe and effective supportive therapies for restoring methylation, glutathione and ATP to near-normal levels in the body, and are likely to help children with autism who experience problems maintaining normal functions," he says.


'/>"/>

Contact: Joe Kullman
joe.kullman@asu.edu
480-965-8122
Arizona State University
Source:Eurekalert

Related biology news :

1. Landmark study unlocks stem cell, DNA secrets to speed therapies
2. Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
3. Mechanisms of cardiovascular disease and cancer give clues to new therapies
4. Pigs and dogs can bridge gap between mice and humans in developing new therapies
5. Digital communication technology helps clear path to personalized therapies
6. Cancer-causing gene discovery suggests new therapies
7. Common gene variants increase risk of hypertension, may lead to new therapies
8. ChemoBrain: How cancer therapies can affect your mind
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. Amniotic fluid may provide new source of stem cells for future therapies
11. Publication sets guidelines across cancer therapies: Ensuring the best in patient management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... ... 04, 2016 , ... Franz Inc. , an early ... has been recognized As “ Best in Semantic Web Technology - USA & ... America, it’s our priority to showcase prominent professionals who are excelling in their ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
Breaking Biology Technology: